Activation of microglia by classical inflammatory mediators can convert astrocytes into a neurotoxic A1 phenotype in a variety of neurological diseases 1, 2 . Development of agents that could inhibit the formation of A1 reactive astrocytes could be used to treat these diseases for which there are no disease-modifying therapies. Glucagon-like peptide-1 receptor (GLP1R) agonists have been indicated as potential neuroprotective agents for neurologic disorders such as Alzheimer's disease and Parkinson's disease [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . The mechanisms by which GLP1R agonists are neuroprotective are not known. Here we show that a potent, brain-penetrant long-acting GLP1R agonist, NLY01, protects against the loss of dopaminergic neurons and behavioral deficits in the α -synuclein preformed fibril (α -syn PFF) mouse model of sporadic Parkinson's disease 14, 15 . NLY01 also prolongs the life and reduces the behavioral deficits and neuropathological abnormalities in the human A53T α -synuclein (hA53T) transgenic mouse model of α -synucleinopathy-induced neurodegeneration 16 . We found that NLY01 is a potent GLP1R agonist with favorable properties that is neuroprotective through the direct prevention of microglialmediated conversion of astrocytes to an A1 neurotoxic phenotype. In light of its favorable properties, NLY01 should be evaluated in the treatment of Parkinson's disease and related neurologic disorders characterized by microglial activation.
NLY01 is a pegylated long-acting GLP1R agonist with an extended half-life and pharmacodynamic profiles in non-human primates (88 h versus the 2 h half-life of exendin-4) and in mice (38 h), while retaining comparable biologic activity to exendin-4 in vitro (Supplementary Fig. 1 and Supplementary Table 1 ). NLY01
does not increase the risk of hypoglycemia when administered in a normoglycemic state in both wild-type and hA53T transgenic mice ( Supplementary Fig. 1g ). NLY01 efficiently penetrates the blood-brain barrier (BBB) in wild-type mice and reaches high brain levels in ten-month-old hA53T transgenic mice ( Supplementary  Fig. 2a-c) . The high levels found in the hA53T transgenic mice may be due to the breakdown of the BBB 5, 17, 18 ( Supplementary Fig. 2d ,e). The neuroprotective potential of NLY01 was first evaluated in the α -syn PFF model of sporadic Parkinson's disease 14, 15 . Recombinant mouse α -syn was purified and depleted of endotoxin, and α -syn PFF was made and validated using atomic force microscopy and transmission electron microscopy and the ability to induce phospho-serine 129 α -synuclein (p-α -syn Ser129 ) was confirmed using immunostaining 15, 19 . We decided to initiate treatment with NLY01 one month after the intrastriatal injection of α -syn PFF, because spread and initial manifestation of pathology in this model starts to become evident at this time point 14, 15 . Six months after the intrastriatal injection of α -syn PFF during which time mice received NLY01 for five months, a number of biochemical and behavioral assays were performed and comparisons were made between mice treated with vehicle (PBS) and mice that received subcutaneous injections of 3 mg kg −1 NLY01 twice a week (Fig. 1a) . As previously described, there is substantial p-α -syn Ser129 immunoreactivity in the striatum and ventral midbrain of α -syn PFF-injected mice indicative of pathologic α -syn 15 ( Fig. 1b,c and Supplementary Fig. 3a-d ). NLY01 significantly reduces p-α -syn Ser129 immunoreactivity in the striatum, ventral midbrain and specifically in tyrosine hydroxylase immunoreactive neurons (Fig. 1b,c and Supplementary Fig. 3a,b) . NLY01 also significantly reduces the amount of pathologic Triton X-100-insoluble α -syn and
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NATuRe MeDIcINe p-α -syn Ser129 as determined by western blot ( Supplementary Fig. 3c,d ). α -Syn PFF injection induces a significant loss of tyrosine hydroxylase-and Nissl-positive neurons in the SNpc, which is prevented by NLY01 (Fig. 1d-f) . Western blot analysis reveals that the α -syn PFF-mediated reduction in tyrosine hydroxylase and dopamine transporter (DAT) immunoreactivity is restored by NLY01 in the ventral midbrain ( Supplementary Fig. 4a,b) . In addition, the α -syn PFF-induced reduction in striatal tyrosine hydroxylase immunoreactivity ( Supplementary Fig. 5a ,b) and the striatal levels of tyrosine hydroxylase and DAT ( Supplementary Fig. 5c,d ) are rescued by Ser129 (green) and tyrosine hydroxylase (TH, red) in the SNpc. White arrows point to loss of dopaminergic neurons. White dashed box in far left panel of (b) outlines area of high magnification in the panels shown to the right. Low-magnification images were generated using the tile scan algorithm in the Zen software (n = 6, biologically independent animals). Scale bars, 100 μ m and 10 μ m for low-and high-magnification images. NLY, NLY01; Veh, vehicle. c, Percentage of tyrosine hydroxylase-positive neurons with p-α -syn Ser129 -positive inclusions in the SNpc region. Data are mean ± s.e.m.; n = 6 biologically independent animals; ***P = 0.0007; unpaired twotailed Student's t-tests were used for statistical analyses. ND, not determined. d, Representative photomicrographs from coronal mesencephalon sections containing tyrosine hydroxylase-positive neurons in the SNpc region. n = 10 biologically independent animals. Scale bar, 500 μ m. Non indicates the noninjected hemisphere. e,f, Unbiased stereologic counts of (e) tyrosine hydroxylase-positive and (f) Nissl-positive neurons in the SNpc region. Data are mean ± s.e.m.; n = 10, biologically independent animals. g, HPLC assessment of dopamine concentrations in the striatum of PBS and α -syn PFF stereotaxic injected mice that were treated with vehicle or NLY01. Data are mean ± s.e.m.; n = 5 biologically independent animals. h,i, Behavioral tests after PBS or α -syn PFF stereotaxic intrastriatal injection at six months in vehicle-or NLY01-treated mice. h, Amphetamine rotation test. i, Pole test. Maximum time to climb down the pole was limited to 60 s. Data are mean ± s.e.m.; n = 12 mice treated with PBS and vehicle, n = 13 mice treated with PBS and NLY01, n = 14 mice treated with α -syn PFF and vehicle and n = 11 mice treated with α -syn PFF and NLY01; n indicate biologically independent animals. A two-way ANOVA was used for statistical analysis followed by a Tukey's multiple comparisons test. #P < 0.05, ##P < 0.01, ###P < 0.001 versus PBS stereotaxic injected mice with vehicle; *P < 0.05, **P < 0.01, ***P < 0.001 versus α -syn PFF stereotaxic injected mice with NLY01. NS, not significant.
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NLY01. α -Syn PFF-induced reductions in dopamine and its metabolites, homovanillic acid, 3-methoxytyramine and 3,4-dihydroxyphenylacetic acid (DOPAC), and the increased DOPAC and homovanillic acid to dopamine ratio and the DOPAC and 3-methoxytyramine to dopamine ratio are normalized by NLY01 treatment (Fig. 1g and Supplementary Fig. 5e-i) . The amphetamine rotation test was used to monitor the behavioral consequences of unilateral α -syn PFF injection. There is marked ipsilateral amphetamine-induced rotation in the α -syn PFF-injected mice, which is prevented by NLY01 (Fig. 1h and Supplementary Fig. 6a ). NLY01 also significantly reduces the behavioral deficits elicited by α -syn PFF injection as measured by the accelerating rotarod test (Supplementary Fig. 6b ) and the pole test ( Fig. 1i and Supplementary Fig. 6c,d ). α -Syn PFF injection also reduces contralateral forepaw touches in the cylinder test, which is restored by NLY01 (Supplementary Fig. 6e ). There are no defects in the ipsilateral forepaw ( Supplementary Fig. 6f ). The increase in grooming time and reduction in rearing induced by α -syn PFF is restored by NLY01 ( Supplementary Fig. 6g,h ).
The effects of NLY01 were further evaluated in a progressive, lethal constitutive α -synucleinopathy model, the hA53T transgenic mouse model 16, 20 . These mice exhibit hyperactivity and evidence of pathologic α -syn formation at four to six months of age 16, 20 . Accordingly, treatment with NLY01 in the hA53T transgenic mice was started at six months of age and the mice were monitored until they were moribund ( Supplementary Fig. 7 ). NLY01 significantly prolongs the lifespan of the hA53T transgenic mice by over 100 days (Fig. 2a) . Accompanying the prolonged survival is a reduction in p-α -syn Ser129 immunoreactivity and aggregated α -syn, and a reduction in ubiquitin immunoreactivity in cells (Fig. 2b-h ). NLY01 also reduces the accumulation of Triton X-100-insoluble α -syn and p-α -syn Ser129 ( Fig. 2i-k) . Taken together, these results indicate that NLY01 protects against the degenerative effects of injected α -syn PFF and constitutive expression of hA53T α -syn.
To determine the potential mechanism of action of NLY01, the expression of GLP1R was assessed in astrocytes, microglia and neuronal cultures. Glp1r mRNA expression is low in the mouse cortex, cerebellum and olfactory bulb, but there are high levels in the striatum, brainstem and ventral midbrain (Fig. 3a) . GLP1R protein is highly expressed in microglia and it is also expressed in astrocytes and neurons with reduced expression (Fig. 3b) , which differs from the in vivo cortical Glp1r mRNA cellular expression profile 21 . This may be due to the regional heterogeneity in Glp1r mRNA expression (Fig. 3a) . α -syn PFF treatment decreases Glp1r mRNA expression in neurons and increases Glp1r mRNA expression almost twofold in microglia (Fig. 3c) . Glp1r mRNA expression is increased more than 10-fold in the substantia nigra of patients with Parkinson's disease compared to controls (Supplementary Fig. 8a and Supplementary Table 2 ). GLP1R immunoreactivity is mainly found in ionized calcium-binding adapter molecule (IBA1) and transmembrane protein 119 (TMEM119) positive microglia in the substantia nigra pars compacta (SNpc) ( Supplementary Fig. 8b-d) . α -syn PFF treatment increases the immunoreactivity of GLP1R in microglia, whereas GLP1R immunoreactivity is found at very low levels in neurons ( Supplementary Fig. 8c,d) , suggesting that the site of action of NLY01 is likely to be predominantly glial-mediated, particularly in the non-cortical brain regions. To determine the mechanism of action of NLY01, the effects of NLY01 on microglial, astrocytic and neuronal cultures were assessed after treatment with α -syn PFF (Fig. 3d) . In human dopaminergic neuronal cultures, direct treatment of NLY01 in the dopaminergic neurons fails to protect against α -syn PFF-induced cell death as assessed by Alamar Blue, lactate dehydrogenase (LDH) and trypan blue assays ( Supplementary Fig. 9a-c) , indicating that the mechanism of action of NLY01 is likely to be upstream in either microglia and/or astrocytes. Previously, we reported that activated microglia convert astrocytes to toxic A1 astrocytes by releasing IL-1α , tumor necrosis factor alpha (TNFα ) and C1q 2 . Therefore, microglia were treated with α -syn PFF for 24 h and then the cytokine profile was assessed using an enzyme-linked immunosorbent assay (ELISA) cytokine screening array. α -syn PFF induces secretion of a variety of cytokines including IL-1α and TNFα . NLY01 reduces the level of a subset of α -syn PFF-induced cytokines including IL-1α , TNFα , IL-1β , IL-6, typical markers of M1 microglia, and leptin ( Supplementary  Fig. 10a ). Because C1q was not present on the ELISA cytokine array, C1q was directly monitored by western blot analysis and compared to TNFα . α -syn PFF induces both C1q and TNFα release into the medium, the release of these factors is significantly inhibited by NLY01 ( Supplementary Fig. 10b,c) . Because NLY01 preferentially blocks microglia-derived factors that induce A1 astrocytes, α -syn PFF microglial-conditioned medium (MCM) was applied to astrocytes for 24 h. The astrocyte-conditioned medium (ACM) was then collected, concentrated and applied to mouse primary cortical cultures and human dopaminergic neurons in the presence or absence of NLY01 (Fig. 3d) . α -syn PFF-ACM kills mouse primary cortical cultures in a dose-dependent manner ( Supplementary Fig. 11a ). NLY01 applied to the α -syn PFF-treated microglia significantly prevents α -syn PFF-ACM-induced cell death in mouse primary cortical cultures ( Supplementary Fig. 11b ) and human dopaminergic neurons ( Supplementary Fig. 11c-e) . The neuronal cell death induced by α -syn PFF-MCM is significantly less than that observed after α -syn PFF-ACM treatment ( Supplementary Fig. 11f,g ), suggesting that α -syn PFF-induced A1 astrocytes are likely to be the primary glial cause that mediates α -syn PFF toxicity. The observations that pretreatment of NLY01 in microglia, but not direct treatment of NLY01 into neurons, significantly reduced the levels of p-α -syn Ser129 induced by α -syn PFF-ACM provide further support for the microglial action of NLY01 ( Supplementary Figs. 12,13) .
To further investigate the ability of α -syn PFF to activate microglia and the inhibitory effect of NLY01, the levels of IL-1α , TNFα , IL-1β , IL-6 and C1q were monitored in response to α -syn PFF. α -syn PFF significantly induces mRNA expression of Il1a, Il1b, Tnf, C1qa and Il6 as determined by quantitative PCR (qPCR) in primary microglia, and NLY01 significantly reduces this mRNA induction (Fig. 3e-g and Supplementary Fig. 10d,e) . Protein levels of IL-1α , TNFα , IL-1β and C1q as determined by ELISA are increased with exposure to α -syn PFF and this induction is reduced by NLY01 (Fig. 3h-j and Supplementary Fig. 10f ). To determine whether α -syn PFF induces microglia activation in vivo, IBA1 immunoreactivity was monitored. Intrastriatal injection of α -syn PFF significantly increases IBA1 immunoreactivity in the SNpc six months after injection and NLY01 significantly reduces the IBA1 immunoreactivity and microglial density (Fig. 3k-m and Supplementary  Fig. 10g ). Western blot analysis of IBA1 expression confirms the induction by α -syn PFF and the reduction by NLY01 (Fig. 3n,o) . Consistent with the primary microglia results, intrastriatal injection of α -syn PFF induces mRNA expresion of Il1a, Il1b, Tnf, C1qa and Il6 in the microglia of the ventral midbrain. This induction is blocked by NLY01 (Fig. 3p-r and Supplementary Fig. 10h,i) . Notably, the inhibitory effect of NLY01 on α -syn PFF-induced A1 microglia activation and α -syn PFF-ACM-induced cell death is prevented by depletion of GLP1R in TMEM119-positive microglia, indicating that NLY01 exhibits protective effects primarily through microglial GLP1R (Supplementary Fig. 14) . NLY01 does not interfere with the uptake of α -syn PFF in microglia, but instead it inhibits the NF-κ B pathway ( Supplementary Fig. 15 ). The further inhibition of α -syn PFF-induced microglia activation by NLY01 in primary microglia from TLR2 knockout mice suggests that the effect of NLY01 is independent of TLR2 signaling 22 ( Supplementary Fig. 16 ). To ascertain whether α -syn PFF-treated microglia induces astrocytes, MCM from α -syn PFF-treated microglia was applied to astrocytes and 24 h later, the expression of glial fibrillary acidic protein (GFAP) was assessed (Fig. 4a) . α -syn PFF-MCM induces
Letters
NATuRe MeDIcINe
GFAP and this induction is blocked by NLY01 (Fig. 4b,c) . To determine what type of astrocytes are induced by α -syn PFF-MCM, general astrocyte reactive, A1-and A2-specific mRNA levels were assessed by qPCR (Fig. 4d) . α -syn PFF-MCM preferentially induces markers of A1 astrocytes, while not perturbing A2-specific transcripts ( Fig. 4d and Supplementary Table 3) . Ser129 and β -actin in detergent (Triton X-100) insoluble fractions and detergent soluble fractions of the brainstem from tenmonth-old wild-type and hA53T α -syn transgenic mice treated with vehicle or NLY01 for four months (cropped blot images are shown, see Supplementary  Fig. 21 for full immunoblots). j, Quantification of α -syn monomer, aggregation and p-α -syn Ser129 protein levels in detergent insoluble fractions normalized to β -actin. Data are mean ± s.e.m.; n = 5 biologically independent animals; ***P < 0.0001. k, Quantification of α -syn monomer and p-α -syn Ser129 protein levels in detergent soluble fractions normalized to β -actin. Data are mean ± s.e.m.; n = 5 biologically independent animals; α -syn, ###P < 0.0001; p-α -syn, P = 0.0002. Unpaired two-tailed Student's t-tests or two-way ANOVAs were used for statistical analysis followed by Tukey's multiple comparisons test. #P < 0.05, ###P < 0.001 versus wild-type mice treated with vehicle; *P < 0.05, ***P < 0.001 versus hA53T α -syn transgenic mice treated with NLY01.
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There is no remaining α -syn PFF in the MCM after the 24-h treatment, indicating that this is not due to the astrocytes responding to α -syn PFF ( Supplementary Fig. 17 ). Notably, treatment of α -syn PFF-MCM with neutralizing antibodies to IL-1α , TNFα , and C1q before the astrocytes were treated prevents A1-type astrocyte formation ( Supplementary Fig. 18a ), and there is no neuronal death in primary cortical neurons ( Supplementary Fig. 18b ,c) and human dopaminergic neurons ( Supplementary Fig. 18d ,e) similar to the effects of NLY01. Taken together, these results indicate that microglia activated by α -syn PFF specifically convert astrocytes to neurotoxic A1 astrocytes and that NLY01 prevents this conversion. Consistent with the glial-enriched expression of GLP1R and the depletion of microglial GLP1R ( Supplementary Fig. 14) , NLY01 treatment of microglia, but not astrocytes, prevents the induction of A1-specific markers ( Fig. 4d and Supplementary Fig. 19 ). Intrastriatal injection of α -syn PFF induces GFAP immunoreactivity ) microglial activation markers. e, Il1a expression. f, Tnf expression. g, C1qa expression. Data are mean ± s.e.m.; n = 3 biologically independent primary microglia cultures. h-j, Cytokine analysis of α -syn PFF-activated microglia-conditioned medium (MCM) 18 h after α -syn PFF treatment by ELISA. NLY01 (1 μ M) pretreatment prevented the increase of IL-1α (h), TNFα (i) and C1q (j). Data are mean ± s.e.m.; n = 4 biologically independent samples treated with primary microglia-conditioned medium. k-m, Inhibition of α -syn PFF-induced microglial activation by NLY01 in vivo. k, Representative immunohistochemical images of IBA1. Scale bar, 50 μ m. l, Intensity of IBA1-positive signals in the SNpc. m, Quantification of IBA1-positive cell number in the SNpc. Data are mean ± s.e.m.; n = 6 biologically independent animals. n, Representative immunoblots of IBA1 and β -actin in the ventral midbrain of PBS and α -syn PFF-injected mice treated with vehicle or NLY01 (cropped blot images are shown, see Supplementary Fig. 21 for full immunoblots). o, Quantification of IBA1 levels in ventral midbrain normalized to β -actin. Data are mean ± s.e.m.; n = 3 biologically independent animals. p-r, qPCR analysis of (p) Il1a, (q) Tnf and (r) C1qa mRNA expression in the ventral midbrain of α -syn PFF-injected mice. Data are mean ± s.e.m.; n = 4 biologically independent animals. Unpaired two-tailed Student's t-tests or two-way ANOVAs were used for statistical analysis followed by Tukey's multiple comparisons test. #P < 0.05, ##P < 0.01, ###P < 0.001 versus PBS with vehicle; *P < 0.05, **P < 0.01, ***P < 0.001 versus α -syn PFF with NLY01.
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NATuRe MeDIcINe in the ventral midbrain, which is blocked by NLY01 (Fig. 4e,f) . Western blot analysis confirms that intrastriatally injected α -syn PFF induction of GFAP expression in the ventral midbrain is blocked by NLY01 (Fig. 4g,h) . Consistent with the induction of A1-specific transcripts, ventral midbrain C3d immunoreactivity is induced by intrastriatally injected α -syn PFF, which is blocked ; n = 5 biologically independent animals. k, Increase in expression of C3 transcripts, which is prevented by NLY01 treatment in α -syn PFF-injected mice. Data are mean ± s.e.m.; n = 4 biologically independent animals. l, qPCR analysis of purified astrocytes from the ventral midbrain of α -syn PFF-injected mice treated with vehicle or NLY01. Data are mean ± s.e.m.; n = 4 biologically independent animals. Two-way ANOVA was used for statistical analysis followed by Tukey's multiple comparisons test. #P < 0.05, ##P < 0.01, ###P < 0.001 versus PBS with vehicle; *P < 0.05, **P < 0.01, ***P < 0.001 versus α -syn PFF with NLY01 or with vehicle.
NATuRe MeDIcINe by NLY01 (Fig. 4g,h ). To evaluate A1 astrocyte formation in the intrastriatally injected α -syn PFF model of sporadic Parkinson's disease, C3d immunohistochemistry was assessed in the ventral midbrain. The number of C3d-positive astrocytes is increased by α -syn PFF; this increase is blocked by NLY01 (Fig. 4i,j) . NLY01 blocks the induction of C3 mRNA in isolated astrocytes in the ventral midbrain following intrastriatally injection of α -syn PFF as determined by qPCR (Fig. 4k) . General astrocyte reactive, A1-and A2-specific mRNA levels were also assessed by qPCR in astrocytes isolated from the ventral midbrain. Intrastriatal injection of α -syn PFF primarily induces A1-specific transcripts and this is prevented by NLY01 (Fig. 4l and Supplementary Table 4 ). Microglial and astrocytic activation has been previously described in the hA53T α -syn transgenic mice 16, 23 . Consistent with these observations, we confirmed both microglial and astrocytic activation as determined by IBA1 and GFAP immunoreactivity, respectively. NLY01 significantly attenuates both microglial ( Supplementary Fig. 20a-c) and astrocytic ( Supplementary Fig. 20d,e) activation. The mRNA levels of the A1 astrocyte marker C3 is markedly increased in tenmonth-old hA53T α -syn transgenic mice and this increase is prevented by NLY01 (Supplementary Fig. 20f ).
The major findings of this paper are the observation that the GLP1R agonist, NLY01 protects in vivo against dopaminergic neuronal loss and behavioral deficits in the intrastriatal injection α -syn PFF mouse model of sporadic Parkinson's disease. Furthermore, NLY01 prolongs the survival and reduces the neuropathology of the hA53T α -syn transgenic mice, a model of familial α -synucleinopathy. The protective effects of NLY01 are independent of its potential action on neurons, but appear to primarily involve inhibition of microglia. We show that α -syn PFF induces microglial activation and that the microglia assume a 'M1'-like phenotype. The M1/M2 microglia nomenclature is under current refinement because microglia clearly can display more than two states 24, 25 . In any event this 'M1' phenotype is consistent with prior reports that aggregated α -syn induces microglial activation and the observations that there are activated microglia in postmortem brains of patients with Parkinson's disease 20, 26 . This M1 microglial activation then converts astrocytes into toxic A1 astrocytes 1 , which contributes to the death of dopaminergic neurons in the α -syn PFF mouse model and in human dopaminergic neuronal cultures as well as contributing to the neurodegeneration in hA53T transgenic mice. Consistent with our findings suggesting that the mechanism of action of NLY01 is through microglia, previous reports showed that the GLP1R agonist, exendin-4, prevents the activation of microglia both in vitro and in vivo following a variety of injury paradigms 11, [27] [28] [29] [30] [31] [32] . There is one report that has shown that exendin-4 does not prevent the activation of microglia in vitro and in vivo following stimulation with lipopolysaccharide 33 . What accounts for the difference in this report with our findings and others is not clear, but it may be due to methodological issues.
GLP1R agonists are protective in models of stroke, traumatic brain injury, Alzheimer's disease and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication model of Parkinson's disease 4, 5, 8, 12, 13 . Notably, the GLP1R agonist, exendin-4, may have a disease-modifying effect in Parkinson's disease 4, 13 . The protective effects of GLP1R agonists have been postulated to involve an insulinotrophic effect, activation of Akt, inhibition of microglial activation, beneficial effects on mitochondrial function through induction of PGC-1α , enhancement of neurogenesis or increased production of trophic factors 30, 34, 35 . Our results provide evidence that GLP1R agonist inhibition of microglia is the primary mechanism of action. Notably, in the α -syn PFF model of sporadic Parkinson's disease and in the hA53T transgenic mouse model, activated microglia express key factors that are responsible for the conversion of astrocytes to toxic A1 astrocytes 1 . This is consistent with what is observed in postmortem brains of patients with Parkinson's disease 2 . NYL01 blocks the microglial activation and the generation of A1 astrocytes. Because of this, NLY01 may have broad neuroprotective properties in a variety of neurodegenerative disorders and neurologic injuries characterized and involving A1 astrocyte activation 2 .
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0051-5. ) two times per week one month after α -syn PFF stereotaxic injection until five months.
hA53T α -synuclein transgenic mice. hA53T α -synuclein transgenic mice were obtained from the Jackson Laboratories (C57BL/6; Prnp-SNCA*A53T) 16 . NLY01 (3 mg kg ) was subcutaneously administered two times per week to six-month-old hA53T α -synuclein transgenic mice until ten-months of age or until death. α-Synuclein purification and α-syn PFF preparation. Recombinant mouse α -synuclein proteins were purified as previously described with an IPTGindependent inducible pRK172 vector system 15, 36 . Endotoxin was depleted by ToxinEraser endotoxin removal kit (Genscript). α -Syn PFF (5 mg ml
) was prepared in PBS while stirring with a magnetic stirrer (1,000 r.p.m. at 37 °C). After a week of incubation of the α -synuclein protein, aggregates were diluted to 0.1 mg ml −1 with PBS and sonicated for 30 s (0.5 s pulse on/off) at 10% amplitude (Branson Digital sonifier, Danbury, CT, USA). α -Syn PFF was validated using atomic force microscopy and transmission electron microscopy, and the ability to induce phospho-serine 129 α -synuclein (p-α -syn Ser129 ) was confirmed using immunostaining 15, 19 . α -Syn PFF was stored at − 80 °C until use.
Preparation of NLY01. NLY01 is pegylated [Cys
40
]exendin-4 and was provided by Neuraly Inc. NLY01 was synthesized as described previously 37, 38 and the corresponding amino acid sequence is His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-AspLeu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-LysAsn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Cys(PEG50K)-NH 2 .
Characterization of NLY01. High Performance Liquid Chromatography analysis.
NLY01 purified by preparative Reverse Phase High Performance Liquid Chromatography was analyzed by using a Dionex Ultimate 3000 HPLC system (Sunnyvale, CA, USA) with a Phenomenex Gemini RP-18 column (250 × 4.6 mm, 5 μ m) at ambient temperature and a constant flow-rate of 1.0 ml min −1 under ultraviolet-light monitoring at 280 nm. The mobile phase consisted of 0.1% trifluoracetic acid (TFA) in deionized water (eluent A) and acetonitrile containing 0.1% TFA (eluent B), and these solutions were applied as linear gradients from 30% B to 60% B over 20 min.
Matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass
spectrometry. The molecular weight of NLY01 was determined by a Bruker Daltonics Microflex MALDI-TOF mass spectrometer (Bremen, Germany) with a 337-nm nitrogen laser. The mass spectrum was obtained in the linear and positiveion mode with an acceleration voltage of 20 kV. As a matrix solution, a saturated solution of sinapinic acid in acetonitrile:water (50:50, v-v) containing 0.1% TFA was used. Each analyte was mixed with a matrix solution at a ratio of 1:1 (analyte:matrix, v-v) and 1 μ l of the analyte-matrix solution was applied and air-dried on the sample plate.
Stereotaxic α-syn PFF injection. For stereotaxic injection of α -syn PFF, threemonth-old male and female mice were anesthetized with xylazene and ketamine. An injection cannula (26.5 gauge) was inserted stereotaxically into the striatum (mediolateral, 2.0 mm from bregma; anteroposterior, 0.2 mm; dorsoventral, 2.6 mm) unilaterally (inserted into the right hemisphere). The infusion was performed at a rate of 0.2 μ l per min, and 2 μ l of α -syn PFF (2.5 μ g μ l −1 in PBS) or the same volume of PBS were injected into the mouse.
Behavioral tests.
To evaluate α -syn PFF-induced behavioral deficits, PBS-and α -syn PFF-injected mice were assessed by pole test, rotarod test, cylinder test and the amphetamine-induced stereotypic rotation test two weeks before death. The experimenter was blinded to treatment group for all behavioral studies. All tests were recorded and performed between 10:00-16:00 in the lights-on cycle.
Amphetamine-induced stereotypic rotation test. Six months after mice received the α -syn PFF injection into the right hemisphere with or without NLY01 treatment, 5 mg kg −1 amphetamine (Sigma-Aldrich) was intraperitoneally administered to the mice. Mice were placed in a white paper cylinder with a 20-cm diameter and monitored for 30 min. The behavior of the mice was filmed at three one-minute intervals between 20 and 30 min following amphetamine administration. Full-body ipsilateral rotations (clockwise) during the one minute session were counted for each mouse from the video recordings.
Pole test. Mice were acclimatized in the behavioral procedure room for 30 min. The pole was made of a 75-cm metal rod with a diameter of 9 mm. It was wrapped with bandage gauze 39 . Mice were placed near the top of the pole (7.5 cm from the top of the pole) facing upwards. The total time taken to reach the base of the pole was recorded. Before the actual test, mice were trained for two consecutive days. Each training session consisted of three test trials. On the test day, mice were evaluated in three sessions and the total time was recorded. The maximum cutoff time to stop the test and recording was 60 s. Results for turn down, climb down and total time (in s) were recorded.
Rotarod test. For the rotarod test, mice were placed on an accelerating rotarod cylinder, and the time the animals remained on the rotarod was measured. The speed was slowly increased from 4 to 40 r.p.m. within 5 min. A trial ended if the animal fell off the rungs or gripped the device and spun around for two consecutive revolutions without attempting to walk on the rungs. The animals were trained 3 days before the test. Motor test data are presented as the percentage of the mean duration (three trials) on the rotarod compared to the control.
Cylinder test. Spontaneous movement was measured by placing animals in a small transparent cylinder (height, 15.5 cm; diameter, 12.7 cm). Spontaneous activity was recorded for 10 min. The number of forepaw touches, rears and grooming were measured. Recorded files were viewed and rated in slow motion by an experimenter blinded to the mouse type and NLY01 treatment.
Immunohistochemistry and quantitative analysis. Immunohistochemistry was performed on 30-μ m thick serial brain sections. Primary antibodies and working dilutions are described in Supplementary Table 5 . Tyrosine hydroxylase, Nissl, p-α -syn Ser129 experimental procedures and quantitative analysis were performed as previously described 39, 40 . Microglia and astrocytes from the SNpc region were stained with anti-IBA1 (Wako, St. Louis, MO, USA) or anti-GFAP (Dako, Santa Clara, CA, USA) antibodies, followed by incubation with biotin-conjugated anti-rabbit antibody and ABC reagents. Sections were developed using SigmaFast DAB Peroxidase Substrate (Sigma-Aldrich). The number of microglia and densities of astrocytes in the SNpc region were measured with ImageJ software.
Immunofluorescence analysis.
Immunofluorescence was performed on 30-μ m thick serial brain sections. Primary antibodies and working dilutions are described in Supplementary Table 5 . For histological studies, immunofluorescence in tissue sections was performed as described previously 15 .
Tissue-and cell-lysate preparation. Tissue lysates were prepared as described previously with some modifications 15 . Non-ionic detergent-soluble and -insoluble fractions were made by homogenization of tissue in brain lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, phosphatase inhibitor cocktail II and III (Sigma-Aldrich) and complete protease inhibitor mixture (Cell Signaling Technology, Danvers, MA, USA)). The homogenate was centrifuged at 22,000g for 20 min, and the resulting pellet and supernatant (soluble part) fractions were collected. The pellet was washed once in brain lysis buffer containing nonionic detergent (0.5% Nonidet P-40) and the resulting pellet (nonionic detergent insoluble) was homogenized in brain lysis buffer containing 1% SDS and 0.5% sodiumdeoxycholate. The homogenate was centrifuged and the resulting supernatant (nonionic detergent insoluble) was collected. Total cell lysates were prepared by homogenization of tissue in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 1% SDS, 0.5% sodium-deoxycholate, phosphatase inhibitor cocktail II and III (Sigma-Aldrich), and complete protease inhibitor mixture). The homogenate was centrifuged at 22,000g for 20 min, and the resulting supernatant (insoluble part) was collected.
Immunoblot analysis. Mouse brain tissues and primary neurons were homogenized and prepared in lysis buffer. Primary antibodies and working dilutions are described in Supplementary Table 5 . Immunoblots of tissue and neuronal culture was performed as described previously 15 . All raw blot and gel images are available in Supplementary Figs. 21,22 .
Measurement of NLY01 accumulation in the brain. The day after the PBS or NLY01 (3 mg kg
) injection in twelve-month-old wild-type and hA53T α -synuclein transgenic mice, the levels of NLY01 in the brain were measured using a exendin-4 (Heloderma suspectum)-EIA Kit (Phoenix Pharmaceuticals, INC, Burlingame, CA, USA), according to the manufacturer's instructions.
Monoamine analysis. High performance liquid chromatography with electrochemical detection was performed to measure biogenic anime concentrations as described previously 39 .
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Differentiation of embryonic stem cells into dopaminergic neurons. The H9 human embryonic stem cells were differentiated into dopaminergic neurons following a dopaminergic neuron induction protocol 41 . All experiments using human stem cells were monitored and approved by the JHU Institutional Stem Cell Research Oversight Committee. Table 2 ). GLP1R mRNA levels were monitored in human postmortem substantia nigra brain tissue from patients with Parkinson's disease and controls (Supplementary Figure 3a) .
Primary neuron, microglia and astrocyte cell cultures. CD1 mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Primary cortical neurons were prepared from embryonic day 15.5 pups and cultured in Neurobasal medium (Gibco) supplemented with B-27, 0.5 mM l-glutamine, penicillin and streptomycin (Invitrogen, Grand Island, NY, USA) on tissue-culture plates coated with poly-l-lysine. The neurons were maintained by changing the medium every 3-4 days. Primary microglial and astrocyte cultures were performed as described previously 42 . Whole brains from mouse pups at postnatal day 1 (P1) were obtained. After removal of the meninges, the brains were washed in DMEM/F12 (Gibco) supplemented with 10% heat-inactivated FBS, 50 U ml −1 penicillin, 50 μ g ml
streptomycin, 2 mM l-glutamine, 100 μ M non-essential amino acids and 2 mM sodium pyruvate (DMEM/F12 complete medium) three times. The brains were transferred to 0.25% trypsin-EDTA followed by 10 min of gentle agitation. DMEM/F12 complete medium was used to stop the trypsinization. The brains were washed three times in this medium again. A single-cell suspension was obtained by trituration. Cell debris and aggregates were removed by passing the single-cell suspension through a 100-μ m nylon mesh. The final single-cell suspension thus achieved was cultured in T75 flasks for 13 days, with a complete medium change on day 6. The mixed glial cell population was separated into astrocyte-rich and microglia-rich fractions using the EasySep Mouse CD11b Positive Selection Kit (StemCell). The magnetically separated fraction containing microglia and the pour-off fraction containing astrocytes were cultured separately. The conditioned medium from the primary microglia treated with α -syn PFF (α -syn PFF-MCM) with either PBS or NLY01 treatment were collected and applied to primary astrocytes for 24 h. The conditioned medium from activated astrocytes by α -syn PFF-MCM, which we define as α -syn PFF-ACM, were collected with complete, Mini, EDTA-free Protease Inhibitor Cocktail (Sigma) and concentrated with Amicon Ultra-15 centrifugal filter unit (10 kDa cutoff) (Millipore) until approximately 50× concentrated. The total protein concentration was determined using Pierce BCA protein assay kit (Thermo Scientific), and 15 or 50 μ g ml
of total protein was added to mouse primary neurons or human dopaminergic neurons, respectively, for the neuronal cell death assay.
pLentiCRISPR GLP1R knockout microglia. The single-guide RNAs targeting GLP1R (KO1, 5′ -CCAGGAGTGGCGCTTCCGTG-3′ ; KO2, 5′ -TCGTGAATGTCAGCTGCCCC-3′ ) were subcloned into a pLentiCRISPR vector (Addgene, Cambridge, MA, USA) and lentivirus was generated as previously described 43 . Microglia were transduced and GLP1R levels were assessed by immunoblot.
Comparative qPCR. Total RNA from cultured cells was extracted with a RNA isolation kit (Qiagen, Valencia, CA, USA) following the instructions provided by the company. RNA concentration was measured spectrophotometrically using a NanoDrop 2000 (Biotek, Winooski, VT, USA). Subsequently, 1-2 μ g of total RNA was reverse transcribed to cDNA using the High-Capacity cDNA Reverse Transcription System (Life Technologies, Grand Island, NY, USA). Comparative qPCR was performed in duplicate or triplicate for each sample using fast SYBR Green Master Mix (Life Technologies) and ViiA 7 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The expression levels of target genes were normalized to the expression of Actb and calculated based on the comparative cycle threshold C t method −ΔΔ (2 ) C t . Names and sequences of primers are summarized in Supplementary Table 6 .
ELISA analysis. The secreted cytokines from primary microglia 18 h after α -syn PFF with either PBS or NLY01 treatment were screened using a mouse cytokine ELISA plate array (Signosis, Santa Clara, CA, USA) according to the manufacturer's instructions.
Cell viability analysis. Cell viability was tested using four methods.
Propidium iodide staining. Primary cultured cortical neurons were treated either with α -syn PFF-ACM or NLY01-α -syn PFF-ACM for 24 h. Cell viability was determined by unbiased objective computer-assisted cell counting after staining of all nuclei with 7 μ M Hoechst 33342 (Invitrogen) and dead cell nuclei with 2 μ M propidium iodide (Invitrogen) 44 . The numbers of total and dead cells were counted with Axiovision 4.3 software (Carl Zeiss). The percentage of cell death was determined as the ratio of live to dead cells compared to the percentage of cell death in control wells to account for cell death attributed to mechanical stimulation of the cultures.
The Alamar Blue and LDH assays. Cell death was assessed using the Alamar Blue assay (Invitrogen) according to the manufacturer's protocol. LDH (Sigma) activity in the culture medium, representing relative cell viability and membrane integrity, was measured using the LDH assay kit spectrophotometrically, following the manufacturer's instructions.
Trypan blue live cell counting. Neurons were dissociated into a single-cell suspension using trypsin. Mixtures of suspended cell and the trypan blue (1:1) solution were immediately put in the live-cell counter (Countess, Invitrogen), and the number of living cells and dead cells was measured. Three wells were assayed for each condition. , n = 2). In addition, the pharmacokinetic profile of NLY01 (1 mg kg −1 , a single subcutaneous injection) was studied in C57BL/6 mice (three mice were used for each time point). Peptide levels were measured using an exendin-4 EIA kit (Phoenix Pharmaceuticals Inc.) in plasma samples collected at various time points. The pharmacokinetic parameters were calculated by non-compartmental analysis using WinNonlin software (Phasight Corporation, Mountain View, CA, USA).
In vitro biological activity of NLY01. GLP1R-transfected HEK293
Cre-Luc-GLP1R cells (GenScript, Piscataway, NJ, USA) were treated with serial dilutions of [Cys 40 ]exendin-4 and NLY01 at the indicated concentrations. After 2 h of incubation, intracellular cAMP levels were measured. Both GLP1R-transfected cells and cAMP detection reagents are part of the intracellular cAMP human recombinant GLP1R stable cell line assay (GenScript). Luminescence was measured using a SpectraMax M5 plate reader. The data were analyzed using a four parameter logistic fit model using Prism software.
Blood glucose level. The hypoglycemic effects of peptides were investigated in age-matched wild-type and hA53T transgenic mice (10 months old). Under nonfasting conditions with free access to food and water, mice were subcutaneously treated with PBS and NLY01 (n = 3, 3 mg kg −1 ). A drop of blood was drawn from a tail vein of each animal at predetermined time points and blood glucose levels were measured using a one-touch blood glucose meter (ACCU-CHEK Sensor, Roche Diagnostics, Indianapolis, IN, USA).
Injection of the fluorescent tracers to assess permeability of the BBB. Fluorescein isothiocyanate-labeled dextran (FITC-dextran, molecular weight 3 kDa, Sigma-Aldrich) and rhodamine-labeled dextran (Rh-dextran, molecular weight 2,000 kDa, Sigma-Aldrich) were used as a gold standard for the evaluation of BBB permeability and disruption. The wild-type and hA53T α -syn transgenic nice were intravenously injected with mixture of FITC-dextran and Rh-dextran in the tail vein, which circulated for 1 h. After 1 h, the mice were euthanized and their brains were quickly removed.
Statistics. All data were analyzed using GraphPad Prism 6 software. Pharmacokinetic parameters were calculated by non-compartmental analysis using WinNonlin software (Phasight Corporation, Mountain View, CA, USA). Data were presented as mean ± s.e.m. with at least three biologically independent experiments. Representative morphological images were taken from at least three biologically independent experiments with similar results. Unpaired two-tailed Student's t-tests or a two-way ANOVAs followed by Tukey's multiple comparisons test were used to assess the statistical significance. Assessments with P < 0.05 were considered significant. 
Reporting
Replication
Describe whether the experimental findings were reliably reproduced.
-All attempts at replication were successful.
-The results of these experiments were obtained by independently different groups and researchers for reliability. In addition, similar results were obtained from other neurodegenerative mice models not shown in the present paper.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
-Behavior test, HPLC (dopamine release, dopamine metabolite level), and cell death assay were randomized.
-Western blot and qPCR data were grouped, but the samples were loaded randomly.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
-In all experiments except Western blot and qPCR, the investigators were blinded to the groups and samples.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
-All data were analyzed using GraphPad Prism 6 software. Statistics the PK parameters were calculated by non-compartmental analysis using WinNonlin software (Phasight Corporation, Mountain View, CA, USA). Data were presented as mean ± S.E.M. with at least 3 biologically independent experiments. Representative morphological images were taken out of at least 3 biologically independent experiments with similar results. An unpaired two-tailed Student's test or an two-way ANOVA test followed by Tukey's multiple comparisons test to assess the statistical significance. Assessments with p < 0.05 were considered significant.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
NLY01 Inc. is only available for distribution by a Neuraly Inc.
-Z.M., V.L.D., S.L., T.M.D., H.S.K are co-founders of Neuraly Inc. and hold ownership equity in the company. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.
-All other experimental materials can be made public and available.
Eukaryotic cell lines
a. State the source of each eukaryotic cell line used.
-We obtained primary neurons from mouse fetal brain, astrocytes and microglia from mouse post-natal brain. We used H9 human embryonic stem cell, which were obtained from WiCEL. We purchased BV2 cell line and HEK-293 from ATCC.
b. Describe the method of cell line authentication used. We used primary neurons, astrocytes, and microglia in this study. As shown in Fig  3b, we conducted western blot analysis to verify that each cell type could be identified with specific antibodies (GFAP, Iba-1, Tuj1). H9 human embryonic stem cell and dopaminergic neuron from H9 embryonic stem cell were not authenticated in his study because the two cells have already been authenticated in previous papers (1) (2) . We used BV2 cell line for testing LPS induced Glp1r mRNA level (Supplementary Figure 16a) . We used HEK-293 cell line. As shown in Supplementary Figure 1f c. Report whether the cell lines were tested for mycoplasma contamination.
-Mycoplasma test for H9 embryonic stem cells was carried out every two weeks using the Mycoalert Mycoplasma Detection Kit (Lonza, LT07-318). We tested mycoplasma contamination before the start of the experiment in primary neurons, astrocytes and microglia cells.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
-There are no commonly misidentified cell lines.
